Supernus Announces Fda Approval Of Qelbreea

Supernus Announces Fda Approval Of Qelbreea

By, Admin 5 April 2021

Supernus Pharmaceuticals, Inc., A Biopharmaceutical Company Focused On Developing And Commercializing Products For The Treatment Of Central Nervous System (Cns) Diseases, Today Announced That The U.S. Food And Drug Administration (Fda) Approved Qelbree (Viloxazine Extended-Release Capsules) For The Treatment Of Attention-Deficit Hyperactivity Disorder (Adhd) In Pediatric Patients 6 To 17 Years Of Age.&Ldquo;Based On The Efficacy Demonstrated In The Clinical Program, We Believe Qelbree Offers A Unique New Alternative For The Treatment Of Adhd,&Rdquo; Said Jack A. Khattar, President And Chief Executive Officer Of Supernus Pharmaceuticals. &Ldquo;Qelbree Provides Prescribing Physicians And Patients Living With Adhd A Therapy That Is Not A Controlled Substance With Proven Efficacy And A Tolerable Safety Profile. We Are Grateful To The Patients, Families And Their Care Givers Who Participated In And Supported Our Research.&Rdquo;&Ldquo;Adhd Is One Of The Most Common Mental Health Issues In The U.S.,&Rdquo; Said Andrew J. Cutler, M.D., Clinical Associate Professor Of Psychiatry At Suny Upstate Medical University, And Chief Medical Officer, Neuroscience Education Institute. &Ldquo;The Right Treatment Is Key For Children And Adolescents, As They Grow And Navigate School And Social Relationships. This Approval Offers A Novel Once A Day Sprinkleable Non-Stimulant That Can Be A Great Option For Children And Adolescents With Adhd.&Rdquo;The Approval Of Qelbree Is Supported By Data From An Extensive Development Program Consisting Of Four Phase Iii Clinical Trials That Studied More Than 1000 Pediatric Patients From The Age Of 6 To 17 Years. In December 2020, The Company Announced Positive Results From A Phase Iii Trial In Adult Patients With Adhd And Plans To Submit A Supplemental New Drug Application To The Fda For Qelbree In Adults In The Second Half Of 2021.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!